Verition Fund Management LLC Acquires 84,316 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Verition Fund Management LLC grew its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 15.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 645,731 shares of the company's stock after purchasing an additional 84,316 shares during the period. Verition Fund Management LLC owned approximately 0.30% of Hims & Hers Health worth $11,894,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in HIMS. Quest Partners LLC raised its stake in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company's stock valued at $81,000 after purchasing an additional 807 shares in the last quarter. CWM LLC raised its position in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after buying an additional 1,054 shares in the last quarter. Arizona State Retirement System raised its position in shares of Hims & Hers Health by 3.0% during the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company's stock worth $815,000 after buying an additional 1,173 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 6.6% in the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company's stock worth $393,000 after acquiring an additional 1,212 shares during the period. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after acquiring an additional 1,603 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Activity

In related news, CFO Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock in a transaction on Monday, October 14th. The stock was sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the sale, the chief financial officer now owns 145,763 shares of the company's stock, valued at approximately $2,960,446.53. This trade represents a 64.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the company's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. The trade was a 84.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,153,519 shares of company stock worth $24,486,721 in the last 90 days. Company insiders own 17.71% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Piper Sandler reissued a "neutral" rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. TD Cowen reissued a "buy" rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Bank of America cut Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their target price for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $24.00 to $28.00 and gave the stock a "buy" rating in a report on Tuesday, November 5th. Finally, Imperial Capital downgraded shares of Hims & Hers Health from an "outperform" rating to an "in-line" rating in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and an average target price of $20.71.

Hims & Hers Health Price Performance

Hims & Hers Health stock traded up $1.88 during midday trading on Friday, reaching $32.22. The stock had a trading volume of 10,258,617 shares, compared to its average volume of 25,601,358. Hims & Hers Health, Inc. has a twelve month low of $8.09 and a twelve month high of $35.02. The firm has a market cap of $7.04 billion, a price-to-earnings ratio of 73.23 and a beta of 1.06. The firm's fifty day simple moving average is $22.01 and its two-hundred day simple moving average is $19.90.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health's revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.04) earnings per share. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.